Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Bedel, Aurélie ^a,b   Pasquet, Jean Max ^a   Lippert, Éric ^a,b   Taillepierre, Miguel ^a   Lagarde, Valérie ^b   Dabernat, Sandrine ^a,b   Dubus, Pierre ^a,b   Charaf, Lucie ^a   Beliveau, François ^a   de Verneuil, Hubert ^a,b   Richard, Emmanuel ^a,b   Mahon, François Xavier ^a,b   Moreau Gaudry, François ^a,b  

^a Bordeaux Institute of Oncology   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL LEVEL; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR CLONING; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PLURIPOTENT STEM CELL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE;

DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HEMATOPOIESIS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 84883034893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071596     Document Type: Article

References (26)

1. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW, (2012) Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12: 513-526 doi:10.1038/nrc3317.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
3. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035 doi:--10.1016/S1470-2045(10)70233-3.
4. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, et al. (2003) Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. N Engl J Med 349: 1423-1432.
5. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99: 319-325.
6. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, et al. (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121: 396-409 doi:10.1172/JCI35721.
7. Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, et al. (2012) Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119: 1501-1510 doi:10.1182/blood-2010-12-326843.
8. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
9. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
10. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
11. Onder TT, Daley GQ, (2012) New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev 22: 500-508 doi:10.1016/j.gde.2012.05.005.
12. Bedel A, Taillepierre M, Guyonnet-Duperat V, Lippert E, Dubus P, et al. (2012) Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors. Am J Hum Genet 91: 109-121 doi:10.1016/j.ajhg.2012.05.026.
13. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, et al. (2011) Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118: 2211-2221 doi:10.1182/blood-2010-10-313692.
14. Belloc F, Airiau K, Jeanneteau M, Garcia M, Guérin E, et al. (2009) The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 23: 679-685 doi:10.1038/leu.2008.364.
15. Woods NB, Parker AS, Moraghebi R, Lutz MK, Firth AL, et al. (2011) Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. Stem Cells 29: 1284-1289 doi:10.1002/stem.657.
16. Coppo P, Dusanter-Fourt I, Vainchenker W, Turhan AG, (2009) BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell Signal 21: 52-60 doi:10.1016/j.cellsig.2008.09.006.
17. Ramos-Mejia V, Fraga MF, Menendez P, (2012) iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 18: 245-247 doi:10.1016/j.molmed.2012.04.001.
18. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, et al. (2010) Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. PNAS 107: 9222-9227 doi:10.1073/pnas.1004584107.
19. Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, et al. (2010) Generation of iPSCs from cultured human malignant cells. Blood 115: 4039-4042 doi:10.1182/blood-2009-07-231845.
20. Hu K, Yu J, Suknuntha K, Tian S, Montgomery K, et al. (2011) Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 117: e109-119 doi:10.1182/blood-2010-07-298331.
21. Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, et al. (2012) Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119: 6234-6242 doi:10.1182/blood-2011-07-367441.
22. Winkler T, Hong SG, Decker JE, Morgan MJ, Wu C, et al. (2013) Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs. J Clin Invest 123: 1952-1963 doi:10.1172/JCI67146.
23. Magee JA, Piskounova E, Morrison SJ, (2012) Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296 doi:10.1016/j.ccr.2012.03.003.
24. Tang M, Foo J, Gonen M, Guilhot J, Mahon FX, et al. (2012) Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica 97: 1553-1561 doi:10.3324/haematol.2012.062844.
25. Ramos-Mejía V, Montes R, Bueno C, Ayllón V, Real PJ, et al. (2012) Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. PLoS One. 7: e35824 doi:10.1371/journal.pone.0035824.
26. Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, et al. (2005) Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer. 103: 102-110.